Vaxart

Vaxart today announced first quarter 2026 financial results. The Company will be hosting a fireside chat tomorrow, May 8 at 4:30 PM ET to answer frequently asked questions from stockholders. Read the full release: bit.ly/4wgdCKX #PillThatMovesTheNeedle $VXRT

#Vaxart will report first quarter 2026 financial results on Thursday, May 7 with a fireside chat on May 8 at 4:30PM ET to answer stockholders' frequently asked questions. The live fireside chat can be accessed here: bit.ly/48DH7MC #PillThatMovesTheNeedle $VXRT

Vaxart appoints James Breitmeyer to its Board of Directors. With more than 35 years of biopharmaceutical experience and eight FDA product approvals, James brings a wealth of knowledge and extensive drug development expertise to Vaxart’s Board. Read more: bit.ly/4vPgwWA

Dr. Sean Tucker, our Founder and CSO, connected with @VaccineInsights to discuss how #Vaxart is reimagining vaccine delivery with oral tablet immunization, what led him to focus on oral vaccines and more. Read the interview: bit.ly/3QcuxNN $VXRT #PillThatMovesTheNeedle

At @vaccinenation, Dr. James F. Cummings, our Chief Medical Officer, shared insights on next generation pandemic vaccine development and how Vaxart’s oral pill vaccine platform can improve how we address public health challenges. #WorldVaccineCongress #WVCDC #Vaxart

Vaxart today announced fourth quarter and full year 2025 financial results. Tune into our conference call today at 4:30 PM ET for key business updates. Read the full release: bit.ly/4bnBfHW $VXRT

$VXRT will host two upcoming conference calls: Full Year 2025 Financial Results Update: March 12 @ 4:30PM ET Vaxart Stockholder Virtual Fireside Chat: March 13 @ 4:30PM ET Call details including webcast links can be found here: bit.ly/4upnQb5 #PillThatMovesTheNeedle

$VXRT today announced that members of the management team will present at the @Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25 at 4:00 PM ET. Register to join the live webcast: bit.ly/4aqbSpx

This #MLKDay, we honor Dr. King's legacy of equality, justice, and hope. Let’s reflect on his impact and how we can build a more inclusive and equitable future together.

$VXRT has announced the publication of positive data for its oral bivalent norovirus candidate in lactating women and their infants. To learn more, read the full release: investors.vaxart.com/news-releases/… Access the publication here: nature.com/articles/s4154…

As 2025 comes to a close, we’re taking a moment to rest, reflect, and recharge. It’s been a year of challenges, growth, and meaningful progress—and we couldn’t have done it without our incredible team, partners, and community. Wishing everyone a joyful and peaceful holiday season

Dr. Sean Tucker, our Founder and CSO, discussed our oral vaccine platform in an interview with Tyler Menichiello of Bioprocess Online. Tune into this informative discussion here (subscription required): bioprocessonline.com/doc/building-a… #PillThatMovesTheNeedle

This Thanksgiving, we’re grateful for our dedicated team and the achievements and the challenges we’ve overcome together. Wishing everyone a peaceful and joyful holiday.

Vaxart today announced third quarter 2025 financial results. Tune into our conference call today at 4:30 PM ET for key business updates. Read the full release: investors.vaxart.com/news-releases/… $VXRT

$VXRT will host two upcoming conference calls: Q3 2025 Financial Results Update: November 13 @ 4:30PM ET Vaxart Stockholder Virtual Fireside Chat: November 18 @ 4:30PM ET Call details including webcast links can be found here: investors.vaxart.com/news-releases/… #PillThatMovesTheNeedle

$VXRT entered an exclusive, worldwide license and commercialization agreement for our investigational oral #COVID19 vaccine candidate with Dynavax. Read the full release: investors.vaxart.com/news-releases/… #PillThatMovesTheNeedle

At #IDWeek2025, Dr. Nick Bennett, Vaxart’s Medical Director, presented Phase 1 #norovirus research featuring Vaxart’s second-generation constructs. Learn more about Vaxart’s novel approach to developing an oral norovirus pill vaccine here: #norovirus" target="_blank" rel="nofollow noopener">vaxart.com/pipeline/#noro… $VXRT

$VXRT will present at #IDWeek2025 in Atlanta. Dr. Nicholas J. Bennett, Vaxart’s Medical Director, will share research on our second-generation norovirus oral pill vaccine candidate. See oral abstract presentation details here: investors.vaxart.com/news-releases/… #Norovirus

At @vaccinenation, Dr. Sean Tucker, our Founder and Chief Scientific Officer, presented research highlighting advancements in our norovirus and COVID-19 oral pill vaccine programs. #Vaxart #WVCEU #WorldVaccineCongress #Covid #Norovirus

An article in @DrugDiscovNews features the promise of Vaxart’s oral pill vaccine platform. Dr. Sean Tucker, Founder and CSO, discusses the potential benefits and science behind our platform and where oral vaccines may be headed next. drugdiscoverynews.com/new-vaccine-pi… $VXRT